Avalanche Biotechnologies (AAVL) Misses Q1 EPS by 18c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NVDA
6. AMAT
7. NRIX
8. SPY
9. OIG
10. BAC

Go back to Avalanche Biotechnologies (AAVL) Misses Q1 EPS by 18c

Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results

May 6, 2016 7:00 AM EDT

MENLO PARK, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today reported financial results for the quarter ended March 31, 2016.

With the announcement of our proposed transaction with Annapurna Therapeutics, the first quarter of 2016 marked a new direction for Avalanche. Our development plans have expanded to include gene therapy programs targeting difficult to treat orphan diseases, said president and chief executive officer of Avalanche, Paul B. Cleveland. We... More